GB201205096D0 - Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity - Google Patents
Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicityInfo
- Publication number
- GB201205096D0 GB201205096D0 GBGB1205096.9A GB201205096A GB201205096D0 GB 201205096 D0 GB201205096 D0 GB 201205096D0 GB 201205096 A GB201205096 A GB 201205096A GB 201205096 D0 GB201205096 D0 GB 201205096D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- iminosugars
- dependent cell
- mediated cytotoxicity
- enhance antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 title 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1205096.9A GB201205096D0 (en) | 2012-03-23 | 2012-03-23 | Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1205096.9A GB201205096D0 (en) | 2012-03-23 | 2012-03-23 | Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201205096D0 true GB201205096D0 (en) | 2012-05-09 |
Family
ID=46086972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1205096.9A Ceased GB201205096D0 (en) | 2012-03-23 | 2012-03-23 | Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB201205096D0 (en) |
-
2012
- 2012-03-23 GB GBGB1205096.9A patent/GB201205096D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212701A1 (en) | Formulations of enzalutamide | |
HK1213798A1 (en) | Therapeutic compounds and compositions | |
ZA201501709B (en) | Cosmetic biphotonic compositions | |
HK1212906A1 (en) | Vaccine compositions | |
HK1207819A1 (en) | Oral composition | |
GB201222285D0 (en) | Cellulose-derived compositions | |
EP2884984A4 (en) | Therapeutic compositions and methods | |
GB201220354D0 (en) | Dermal compositions | |
IL237431A0 (en) | Immunogenic compositions | |
SI2874635T1 (en) | Therapeutic bacteriophage compositions | |
EP2752186A4 (en) | Skin cleanser composition | |
IL239569A0 (en) | Anti-plaque oral compositions | |
EP2821053A4 (en) | Skin cleanser composition | |
EP2897613A4 (en) | Treatment compositions | |
HK1205954A1 (en) | Companion cosmetic compositions | |
IL236312A0 (en) | Preparation of 18f-fluciclovine | |
PL2734192T3 (en) | Effervescent dosage form | |
EP2752185A4 (en) | Skin cleanser composition | |
EP2821054A4 (en) | Skin cleanser composition | |
GB201210873D0 (en) | Therapeutic composition | |
IL217807A0 (en) | Therapeutic compositions | |
HK1214755A1 (en) | Dental compositions | |
EP2859881A4 (en) | Oral composition | |
GB201205096D0 (en) | Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity | |
GB201104878D0 (en) | Use of iminosugars to enhance antibody-dependent cell-mediated cytotoxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |